

CLAIMS

1. Use of at least one PTHrP antagonist for preparing a pharmaceutical composition for treating preventatively or curatively kidney cancer and in particular
5 renal cell carcinoma (RCC) in a mammal and in particular in a human subject

2. Use according to the preceding claim, characterised in that the composition is aiming to treat papillary carcinoma (chromophiles), chromophobe cell carcinoma, Bellini carcinoma or unclassified renal cell carcinomas or
10 preferably clear cell carcinoma (CCC).

3. Use according to one of the preceding claims, characterised in that the composition is aiming to inhibit or decrease the tumour growth and / or metastasis formation in kidney cancer and / or its metastatic developments, in particular in the
15 lung and the liver.

4. Use according to one of the preceding claims, characterised in that the composition is aiming to treat malignant tumours of kidney cancer, more specifically the treatment of solid malignant tumours.

20

5. Use according to one of the preceding claims, characterised in that the PTHrP antagonist is a compound binding the PTHrP receptor, inhibiting partially, or even totally, the binding of PTHrP to its receptor.

25 6. Use according to claim 5, characterised in that the PTHrP antagonist is a PTHrP receptor antagonist and preferably a PTHrP competitive antagonist.

7. Use according to one of the claims 5 and 6, characterised in that the PTHrP antagonist is selected from PTH or PTHrP peptides comprising a
30 substitution or a deletion of at least one amino acid of the sequence of PTH or PTHrP or a partial sequence of the peptide PTH or PTHrP, optionally comprising a substitution or a deletion of at least one amino acid of their sequence.

8. Use according to one of the claims 5 to 7, characterised in that the PTHrP antagonist is selected from PTHrP (3-34), PTHrP (7-34), PTHrP (8-34), PTHrP (9-34), PTHrP (10-34), their amides and their variants.

5 9. Use according to one of the claims 5 to 7, characterised in that the PTHrP antagonist is a non-peptidic antagonist.

10 10. Use according to one of the claims 5 to 7, characterised in that the PTHrP antagonist is a TIP derivative.

11. Use according to one of the claims 1 to 4, characterised in that the PTHrP antagonist is a compound binding a ligand of the PTHrP receptor, inhibiting partially, or even totally, the binding of PTHrP to its receptor.

15 12. Use according to the preceding claim, characterised in that the PTHrP antagonist is an anti-PTHrP antibody and preferably a humanised anti-PTHrP antibody.

20 13. Use according to the preceding claim, characterised in that the anti-PTHrP antibody is selected from a humanised antibody, a human antibody, a chimeric antibody, an antibody obtained from a hybridoma or a fragment thereof and / or a modified form of said fragment.

25 14. Use according to one of the claims 12 and 13, characterised in that the anti-PTHrP antibody is a polyclonal antibody or preferably monoclonal antibody.

15. Use according to one of the claims 1 to 4, characterised in that the PTHrP antagonist is a compound binding to the mRNA or gene of PTHrP, inhibiting partially, or even totally, the expression of PTHrP.

30 16. Use according to the preceding claim, characterised in that the PTHrP antagonist is an antisense oligonucleotide of PTHrP, a RNAi, a transcription factor repressing the expression of the PTHrP gene or a compound reducing the stability of the PTHrP mRNA.